Heart drug hope: diabetes meds may help adults born with heart defects

NCT ID NCT06932081

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This international registry is tracking 400 adults with congenital heart disease who are taking SGLT2 inhibitors, a type of diabetes medication that also benefits the heart. Researchers want to see how these drugs are being prescribed, how well they are tolerated, and whether they improve heart failure outcomes. The study is purely observational, meaning it collects real-world data without assigning treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SGLT2 inhibitors (a class of diabetes drugs that help the heart and kidneys)

What this could lead to

If successful, this registry could show that SGLT2 inhibitors are safe and helpful for adults with congenital heart disease, potentially leading to better heart failure management.

What could go wrong

This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors, and the study is relatively small (400 participants).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETRALOGY OF FALLOT (TOF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease congenitally corrected transposition of the great arteries heart failure tetralogy of fallot transposition of the great arteries univentricular heart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

    Contact

  • Barts Heart Centre

    RECRUITING

    London, United Kingdom

    Contact

  • Golden Jubilee University National Hospital

    RECRUITING

    Glasgow, United Kingdom

    Contact

  • Heart Center Duisburg (Evangelical Hospital Niederrhein)

    RECRUITING

    Duisburg, Germany

    Contact

    Contact

  • Helen DeVos Children's Hospital

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

    Contact

  • Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21205, United States

    Contact

  • Leiden University Medical Center (LUMC)

    RECRUITING

    Leiden, South Holland, 2333ZA, Netherlands

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mount Sinai Fuster Heart Hospital

    RECRUITING

    New York, New York, 10029, United States

    Contact

  • University Hospital of Wales

    RECRUITING

    Cardiff, United Kingdom

    Contact

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Netherlands

    Contact

  • Zan Mitrev Clinic

    RECRUITING

    Skopje, North Macedonia

    Contact